Optimizing Effectiveness of Smoking Cessation Intervention During LDCT screening for Lung Cancer
优化 LDCT 肺癌筛查期间戒烟干预的有效性
基本信息
- 批准号:10248389
- 负责人:
- 金额:$ 31.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AbstinenceAccountingAdvisory CommitteesAftercareCancer EtiologyCaringCessation of lifeCommunitiesCounselingCountryDropsEffectivenessEnvironmentGoalsGoldGuidelinesHealthIndividualInterventionLungMalignant NeoplasmsMalignant neoplasm of lungMediatingMedicalMedication ManagementMental HealthMethodsModalityModelingMotivationNational Comprehensive Cancer NetworkPatientsPharmacotherapyPlayPreventive serviceProbabilityProviderPublic HealthRandomizedRecommendationRelapseResearchResource AllocationRiskRoleSelf EfficacyServicesSmokerSmokingSmoking Cessation InterventionSpecialistStressThoracic RadiographyTimeTobaccoTobacco useTreatment outcomeUnited StatesUnited States Public Health ServiceVisitWomanbasebehavior changebrief adviceclinical practicecomputed tomography screeningcostcost effectivecost effective treatmentcost effectivenesscost-effectiveness evaluationefficacy evaluationefficacy testingevidence baseflexibilityhealth care settingshigh riskimprovedinterestlow dose computed tomographylung cancer screeningmenmortalitynegative affectnicotine replacementprogramsquitlinerelative costrelative effectivenessscale upscreeningsmoking abstinencesmoking cessationstandard caresuccesstreatment effecttreatment strategy
项目摘要
PROJECT SUMMARY
The low-dose computed tomography (LDCT) lung cancer screening environment may provide a unique
opportunity to deliver evidence-based smoking cessation treatments at a time where smokers' interest in health
concerns may make them particularly receptive to a quitting message. While there are well established
methods for smoking cessation in the general community, the optimal configuration of a smoking cessation
intervention in a real-world lung cancer screening setting has not been established. It seems clear that such
interventions should go beyond the provision of passively providing smoking cessation advice, but the
intervention modality, level of intensity and degree of integration with the screening setting is unknown.
Despite enthusiasm for integrating smoking cessation programs within health care settings there have been few
attempts to actually develop such programs. The proposed research will be among the first to focus on
identifying the optimal configuration for integrating a program into the LDCT for lung cancer screening. This
study will also ascertain the cost-effectiveness and value of implementation of increasingly more integrative
and intensive strategies. This will enable decision makers and other stakeholders to assemble a cessation
program that provides maximum effectiveness while considering resource allocation efficiency within their
LDCT screening environment. The present proposal focuses on the relative effectiveness and cost of three
major components of a smoking cessation intervention: a publically available cessation quitline; level of
involvement of LDCT medical providers; and integration of smoking cessation specialists within the LDCT
setting. Smokers (N=630) will be randomly assigned to three groups: Quitline (QL); Quitline-Rx (QL-Rx); and
Integrated Care (IC). The QL intervention is intended to model the real-world situation in which smokers
who present for lung cancer screening are provided standard care (brief advice for smoking cessation) and
referred to the quitline for smoking cessation counseling and nicotine replacement therapy. The Quitline-Rx
group is intended to model an environment in which the LDCT medical provider assumes an active role in
selecting and managing available pharmacotherapy for smoking cessation, and the quitline serves as the
provider for smoking cessation counseling. The Integrated Care intervention (IC) presents the highest level of
care and is models an environment in which smoking cessation counseling and medication management are
provide by smoking cessation specialists within that setting. The major contribution of this research is
expected to be a change in clinical practice and advancing a model for providing integrated smoking cessation
treatment as a “gold” standard for LDCT lung cancer screening settings across the country. Ultimately the
availability of smoking cessation services will enhance the impact of lung cancer screening on the public health
by reducing smoking related illness.
项目摘要
低剂量计算机断层扫描(LDCT)肺癌筛查环境可能提供独特的
在吸烟者对健康感兴趣的时候提供循证戒烟治疗的机会
担忧可能使他们特别容易接受辞职的信息。虽然有一些已经建立的
戒烟方法在一般社会中,戒烟的最佳配置
在现实世界的肺癌筛查环境中的干预尚未建立。显然,这样的
干预措施应超越被动提供戒烟建议的规定,但
干预方式、强度水平和与筛查环境的整合程度尚不清楚。
尽管人们热衷于将戒烟计划纳入医疗保健环境,
实际上是在开发这样的项目。这项拟议中的研究将是第一批关注
识别用于将程序整合到用于肺癌筛查的LDCT中的最佳配置。这
研究还将确定实施日益一体化的
强化战略。这将使决策者和其他利益相关者能够聚集一个停止
提供最大效率的计划,同时考虑其内部的资源分配效率
LDCT筛查环境。本建议侧重于三个方面的相对有效性和成本
戒烟干预的主要组成部分:可获得的戒烟热线;
LDCT医疗提供者的参与;以及LDCT内戒烟专家的整合
设置.吸烟者(N=630)将被随机分配到三组:Quitline(QL); Quitline-Rx(QL-Rx);和
综合护理(IC)。QL干预旨在模拟吸烟者的真实情况,
为参加肺癌筛查的人提供标准护理(戒烟的简短建议),
戒烟咨询和尼古丁替代疗法。Quitline-Rx
小组旨在模拟一种环境,在这种环境中,LDCT医疗提供者在以下方面发挥积极作用:
选择和管理可用的戒烟药物治疗,戒烟热线作为
提供戒烟咨询。综合护理干预(IC)提供了最高水平的
护理并模拟了一个戒烟咨询和药物管理的环境
由戒烟专家在该环境中提供。这项研究的主要贡献是
预计将成为临床实践的一个变化,并推进提供综合戒烟的模式
作为全国LDCT肺癌筛查设置的“金”标准。最终
提供戒烟服务将加强肺癌筛查对公众健康的影响
通过减少与吸烟相关的疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAUL MICHAEL CINCIRIPINI其他文献
PAUL MICHAEL CINCIRIPINI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAUL MICHAEL CINCIRIPINI', 18)}}的其他基金
The potential risks and benefits of electronic cigarettes to older smokers at high risk for lung cancer
电子烟对肺癌高危老年吸烟者的潜在风险和益处
- 批准号:
10248295 - 财政年份:2020
- 资助金额:
$ 31.65万 - 项目类别:
The potential risks and benefits of electronic cigarettes to older smokers at high risk for lung cancer
电子烟对肺癌高危老年吸烟者的潜在风险和益处
- 批准号:
10413235 - 财政年份:2020
- 资助金额:
$ 31.65万 - 项目类别:
Optimizing Effectiveness of Smoking Cessation Intervention During LDCT screening for Lung Cancer
优化 LDCT 肺癌筛查期间戒烟干预的有效性
- 批准号:
9160962 - 财政年份:2016
- 资助金额:
$ 31.65万 - 项目类别:
Evaluating Concomitant Use of Very Low Nicotine Content Cigarettes and E-cigarettes Among Daily and Non-Daily Smokers on Abuse Liability
评估日常和非日常吸烟者同时使用尼古丁含量极低的香烟和电子烟的滥用责任
- 批准号:
9490473 - 财政年份:2016
- 资助金额:
$ 31.65万 - 项目类别:
Evaluating Concomitant Use of Very Low Nicotine Content Cigarettes and E-cigarettes Among Daily and Non-Daily Smokers on Abuse Liability
评估日常和非日常吸烟者同时使用尼古丁含量极低的香烟和电子烟的滥用责任
- 批准号:
9193508 - 财政年份:2016
- 资助金额:
$ 31.65万 - 项目类别:
MD Anderson Cancer Center, University of Texas Clinical Trial Site
德克萨斯大学 MD 安德森癌症中心临床试验中心
- 批准号:
8127171 - 财政年份:2010
- 资助金额:
$ 31.65万 - 项目类别:
Effectiveness of Varenicline vs. Varenicline plus Bupropion for Smoking Cessation
伐尼克兰与伐尼克兰加安非他酮的戒烟效果对比
- 批准号:
8417027 - 财政年份:2009
- 资助金额:
$ 31.65万 - 项目类别:
Effectiveness of Varenicline vs. Varenicline plus Bupropion for Smoking Cessation
伐尼克兰与伐尼克兰加安非他酮的戒烟效果对比
- 批准号:
8588300 - 财政年份:2009
- 资助金额:
$ 31.65万 - 项目类别:
Error Sensitivity as a Predictor of Nicotine Withdrawal & Smoking Cessation
误差敏感性作为尼古丁戒断的预测指标
- 批准号:
7641972 - 财政年份:2009
- 资助金额:
$ 31.65万 - 项目类别:
Effectiveness of Varenicline vs. Varenicline plus Bupropion for Smoking Cessation
伐尼克兰与伐尼克兰加安非他酮的戒烟效果对比
- 批准号:
7797630 - 财政年份:2009
- 资助金额:
$ 31.65万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 31.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 31.65万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 31.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 31.65万 - 项目类别:
Standard Grant
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 31.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 31.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 31.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 31.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 31.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 31.65万 - 项目类别:














{{item.name}}会员




